Our inspiration will always be the patients we strive to serve. We continually connect with patients affected by life-threatening bone marrow conditions – letting their stories inform and inspire our path forward. We are determined to change the natural history of diseases of the bone marrow, and the patient is the guide who will lead us toward this mission.
Our singular focus is our strength. In directing our efforts toward advancing lysine-specific demethylase 1 (LSD1) research, we believe we can have the greatest chance of impacting a specific group of related diseases. LSD1 is an enzyme playing a critical role in the behavior of malignant blood cells, notably, in determining which genes are turned ‘on’ versus ‘off.’ Our lead therapeutic candidate, bomedemstat, is a small molecule inhibitor of LSD1 currently being investigated in clinical trials.